Modufolin® is a folate-based bio-modulator designed to replace leucovorin/levoleucovorin as the preferred treatment to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-flluorouracil). It is currently being evaluated in three Phase I/II studies, two in colorectal cancer and one in osteosarcoma. Read more about Modufolin
Although several modern chemo drugs have been introduced that dramatically improve the treatment of many cancer diseases, they show limited effect in treating solid tumors. 5-FU and leucovorin/levoleucovorin is still the core treatment used today for colorectal cancer and Modufolin® has the potential to enable 5-FU to work more effectively.
Click the link below to stay informed about our progress.
To find out the latest news about our ongoing clinical phase II trial please go to:
Click the link below to find out more about our development pipeline:
News & Press information
Stockholm Corporate Finance Life Science Day 2015
Isofol’s Chief Scientific Officer, Anders Vedin will present the company at the Stockholm Corporate Finance Life Science Day 2015 at 13:45am on March 4, at Operaterrassen in Stockholm.
Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset
Gothenburg, Sweden, Cambridge UK, and Clinton NJ – February 2015 – Isofol (www.isofolmedical.com), a clinical stage pharmaceutical company based in Gothenburg, Sweden, announces that following an internal review, it has launched a global program to identify one or more strategic partners for commercialization of its Modufolin® chemotherapy asset. The Sage Group (based in Europe, USA and Asia) has been appointed by Isofol to assist the company in this endeavor. The overall objective is to identify a well-‐established pharma partner who will work with the company to exploit the value of Modufolin® in what is believed to be a multi billion dollar market.